Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms

Titre officiel

A Multicentre, Long-term Extension Study to Further Evaluate the Safety and Tolerability of Telotristat Etiprate (LX1606)

Sommaire:

L’objectif principal de cette étude est d’évaluer l’innocuité et la tolérabilité à long terme du télotristat étiprate administré par voie orale.

Description de l'essai

Primary Outcome:

• Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

• Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30) Score at Each Visit
• Change From Baseline in Gastrointestinal Symptoms of Carcinoid Neuroendocrine Tumours (GI.NET21) Score at Each Visit
• Percentage of Participants With Adequate Relief as Per Subjective Global Assessment Question
• Change From Baseline in Subjective Global Assessment of Carcinoid Syndrome Symptoms on 11-Point Numeric Scale at Each Visit

Voir cet essai sur ClinicalTrials.gov